Recombinant Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR7278] to Hsp27 (phospho S82)
- Suitable for: WB, IP, Dot blot
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-Hsp27 (phospho S82) antibody [EPR7278]
See all Hsp27 primary antibodies -
Description
Rabbit monoclonal [EPR7278] to Hsp27 (phospho S82) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IP, Dot blotmore details
Unsuitable for: Flow Cyt,ICC/IF or IHC-P -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- HeLa cell lysate treated with heat shock (44°C); Human skeletal muscle and urinary bladder transitional carcinoma tissues.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20ºC. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR7278 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab155987 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/2000. Predicted molecular weight: 23 kDa.
For unpurified, use 1/200. |
|
IP |
1/75.
For unpurified, use 1/10. |
|
Dot blot |
1/1000.
|
Notes |
---|
WB
1/1000 - 1/2000. Predicted molecular weight: 23 kDa. For unpurified, use 1/200. |
IP
1/75. For unpurified, use 1/10. |
Dot blot
1/1000. |
Target
-
Function
Involved in stress resistance and actin organization. -
Tissue specificity
Detected in all tissues tested: skeletal muscle, heart, aorta, large intestine, small intestine, stomach, esophagus, bladder, adrenal gland, thyroid, pancreas, testis, adipose tissue, kidney, liver, spleen, cerebral cortex, blood serum and cerebrospinal fluid. Highest levels are found in the heart and in tissues composed of striated and smooth muscle. -
Involvement in disease
Defects in HSPB1 are the cause of Charcot-Marie-Tooth disease type 2F (CMT2F) [MIM:606595]. CMT2F is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Nerve conduction velocities are normal or slightly reduced. CMT2F onset is between 15 and 25 years with muscle weakness and atrophy usually beginning in feet and legs (peroneal distribution). Upper limb involvement occurs later. CMT2F inheritance is autosomal dominant.
Defects in HSPB1 are a cause of distal hereditary motor neuronopathy type 2B (HMN2B) [MIM:608634]. Distal hereditary motor neuronopathies constitute a heterogeneous group of neuromuscular disorders caused by selective impairment of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. -
Sequence similarities
Belongs to the small heat shock protein (HSP20) family. -
Post-translational
modificationsPhosphorylated in MCF-7 cells on exposure to protein kinase C activators and heat shock. -
Cellular localization
Cytoplasm. Nucleus. Cytoplasm > cytoskeleton > spindle. Cytoplasmic in interphase cells. Colocalizes with mitotic spindles in mitotic cells. Translocates to the nucleus during heat shock and resides in sub-nuclear structures known as SC35 speckles or nuclear splicing speckles. - Information by UniProt
-
Database links
- Entrez Gene: 3315 Human
- Entrez Gene: 15507 Mouse
- Entrez Gene: 24471 Rat
- Omim: 602195 Human
- SwissProt: P04792 Human
- SwissProt: P14602 Mouse
- SwissProt: P42930 Rat
- Unigene: 520973 Human
see all -
Alternative names
- Heat shock 27kDa protein antibody
- 28 kDa heat shock protein antibody
- CMT2F antibody
see all
Images
-
All lanes : Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/1000 dilution
Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) with 44°C heat shock whole cell lysates
Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysates
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/20000 dilution
Predicted band size: 23 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted?
Exposure time: 1 minuteBlocking and diluting buffer: 5% NFDM/TBST.
-
Dot blot analysis of Lane 1: Hsp27 (pS82) phospho peptide and Lane 2: Hsp27 non-phospho peptide, labeling Hsp27 (phospho S82) with ab155987 at 1/1000 dilution. 5% NFDM/TBST was used as the blocking and diluting buffer. ab97051, a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated secondary antibody was used at 1/100000 dilution. Exposure time: 10 seconds.
-
All lanes : Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/1500 dilution (purified)
Lane 1 : Mouse heart
Lane 2 : Rat heart
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 23 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/1500 dilution (purified) + HeLa cell lysate treated with heat shock (44°C) at 10 µg
Secondary
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 23 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
ab155987 (purified) at 1/75 immunoprecipitating Hsp27 (phospho S82) in HeLa cell lysate treated with heat shock (44°C) (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
All lanes : Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/200 dilution (unpurified)
Lane 1 : Mouse heart
Lane 2 : Rat heart
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 23 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/200 dilution (unpurified) + HeLa cells treated with heat shock (44°C) at 10 µg
Secondary
HRP goat anti-rabbit (H+L) at 1/1000 dilution
Predicted band size: 23 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted?Blocking buffer: 5% NFDM/TBST
Dilution buffer: 5% NFDM/TBST
-
All lanes : Anti-Hsp27 (phospho S82) antibody [EPR7278] (ab155987) at 1/1000 dilution (unpurified)
Lane 1 : Untreated HeLa cell lysate
Lane 2 : HeLa cell lysate treated with heat shock (44°C)
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat anti-rabbit HRP at 1/2000 dilution
Predicted band size: 23 kDa -
ab155987 (unpurified) at 1/75 immunoprecipitating Hsp27 (phospho S82) in HeLa cell lysate treated with heat shock (44°C) (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (5)
ab155987 has been referenced in 5 publications.
- He H et al. Copper Oxide Nanoparticles Induce Oxidative DNA Damage and Cell Death via Copper Ion-Mediated P38 MAPK Activation in Vascular Endothelial Cells. Int J Nanomedicine 15:3291-3302 (2020). PubMed: 32494130
- Okada J et al. FAM83G Is a Novel Inducer of Apoptosis. Molecules 25:N/A (2020). PubMed: 32570757
- Fang Z et al. HSP27 promotes epithelial-mesenchymal transition through activation of the β-catenin/MMP3 pathway in pancreatic ductal adenocarcinoma cells. Transl Cancer Res 8:1268-1278 (2019). PubMed: 35116869
- Gorter RP et al. Heat shock proteins are differentially expressed in brain and spinal cord: implications for multiple sclerosis. Clin Exp Immunol N/A:N/A (2018). PubMed: 30014472
- Rao W et al. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells. Carcinogenesis N/A:N/A (2014). PubMed: 24667688